Impact of tranilast on restenosis after coronary angioplasty: Tranilast Restenosis Following Angioplasty Trial (TREAT)☆,☆☆
Section snippets
Inclusion criteria and patient population
The inclusion criteria in this study were angina pectoris or old myocardial infarction, de novo native coronary lesions, type A or B lesions of the American Heart Association/American College of Cardiology (AHA/ACC) classification, age ≤75 years, Thrombolysis in Myocardial Infarction (TIMI) flow grade 2 or 3, lesion stenosis >50% by measurement, and successful PTCA. Successful PTCA was defined as dilation of the lesions with <50% residual stenosis and a >20% decrease in percent diameter
Characteristics of patients and lesions
A total of 255 patients (289 lesions) consented to participate; 85 patients (95 lesions) were assigned to the placebo group, 84 patients (94 lesions) to the T300 group, and 86 patients (100 lesions) to the T600 group. The intention-to-treat population consisted of 247 patients (279 lesions) among those who fulfilled all inclusion criteria and received at least 1 dose of test medication. There were no significant differences among the 3 groups regarding all clinical characteristics including
Discussion
In the current study, the restenosis rate estimated with 2 different definitions was significantly decreased by 600 mg/d of tranilast. The 12-month clinical follow-up revealed a favorable target lesion revascularization rate in the T600 group. These results show the impact of tranilast at 600 mg/d for 3 months on preventing angiographic and clinical restenosis. Although the approved dose of tranilast as an antiallergic drug and an antikeloid drug in Japan is 300 mg/d, this dosage of tranilast
Acknowledgements
We thank Dr Kinzo Ueda and Dr Eisho Kyo for their help in the data collection and analysis. We also thank Dr Kunihiko Kosuga and Daniel Mrozek for their help in the preparation of the manuscript.
References (25)
- et al.
Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients
J Am Coll Cardiol
(1988) - et al.
Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty
Am Heart J
(1995) - et al.
Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients
J Am Coll Cardiol
(1991) - et al.
Arterial injury and the enigma of coronary restenosis
J Am Coll Cardiol
(1992) - et al.
The restenosis paradigm revisited: an alternative proposal for cellular mechanisms
J Am Coll Cardiol
(1992) - et al.
Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats
Atherosclerosis
(1995) - et al.
Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells
Atherosclerosis
(1994) - et al.
Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet
Eur J Pharmacol
(1996) - et al.
Effectiveness of tranilast on restenosis after directional coronary atherectomy
Am Heart J
(1997) - et al.
Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute
Am J Cardiol
(1984)
Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months
Circulation
Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, double-blind STARC study
Circulation
Cited by (0)
- ☆
Reprint requests: Hideo Tamai, MD, Department of Cardiology, Shiga Medical Center for Adults, 5-4-30, Moriyama, Moriyama, Shiga, Japan.
- ☆☆
0002-8703/99/$8.00 + 0 4/1/99846